Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2

Autor: Yee Sin Leo, Chee Wah Tan, Yee-Joo Tan, Martin Linster, Barnaby Edward Young, Danielle E. Anderson, Wan Ni Chia, Mark I-Cheng Chen, Gavin J. D. Smith, David C. Lye, JennyG. H. Low, Lin-Fa Wang
Jazyk: angličtina
Rok vydání: 2020
Předmět:
0301 basic medicine
Time Factors
Letter
Epidemiology
viruses
Antibodies
Viral
Severe Acute Respiratory Syndrome
medicine.disease_cause
Serology
antibody
Drug Discovery
Medicine
skin and connective tissue diseases
COVID-19
cross-neutralization
SARS
SARS-CoV-2
Coronavirus
biology
Viral Vaccine
General Medicine
Infectious Diseases
Severe acute respiratory syndrome-related coronavirus
Antibody
Coronavirus Infections
Pneumonia
Viral
030106 microbiology
Immunology
Microbiology
Betacoronavirus
03 medical and health sciences
Virology
Humans
Pandemics
COVID-19 Serotherapy
Virus classification
business.industry
fungi
Immunization
Passive
Viral Vaccines
Vaccine efficacy
biology.organism_classification
body regions
030104 developmental biology
Immunization
biology.protein
Parasitology
business
Broadly Neutralizing Antibodies
Zdroj: Emerging Microbes & Infections
Emerging Microbes & Infections, 9(1):900-902
ISSN: 2222-1751
DOI: 10.1080/22221751.2020.1761267
Popis: Despite initial findings indicating that SARS-CoV and SARS-CoV-2 are genetically related belonging to the same virus species and that the two viruses used the same entry receptor, angiotensin-converting enzyme 2 (ACE2), our data demonstrated that there is no detectable cross-neutralization by SARS patient sera against SARS-CoV-2. We also found that there are significant levels of neutralizing antibodies in recovered SARS patients 9–17 years after initial infection. These findings will be of significant use in guiding the development of serologic tests, formulating convalescent plasma therapy strategies, and assessing the longevity of protective immunity for SARS-related coronaviruses in general as well as vaccine efficacy.
Databáze: OpenAIRE
Externí odkaz: